Alphatec (NASDAQ:ATEC) Reaches New 52-Week Low Following Weak Earnings

Key Points

• Alphatec shares fell 33.3% to a new 52-week low after the company reported quarterly EPS of $0.09 and revenue of $221.17 million, both slightly below analyst expectations.
• Revenue still increased 12.6% year over year, but the company remained unprofitable and lowered its 2026 revenue forecast to $862 million from market expectations of about $882 million.
• BMO Capital Markets downgraded the stock to “market perform” with an $8 price target, despite the broader analyst consensus remaining “Moderate Buy” with a $17 target.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) reached a new 52-week low during trading on Friday following a weaker than expected earnings announcement. The company traded as low as $6.81 and last traded at $7.7010, with a volume of 3,777,722 shares changing hands. The stock had previously closed at $11.37.

The medical technology company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). The firm had revenue of $221.17 million during the quarter, compared to the consensus estimate of $225.16 million. Alphatec had a negative net margin of 13.49% and a negative return on equity of 6,752.24%. The firm's revenue was up 12.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.03 EPS.

Alphatec News Roundup

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Third-quarter revenue rose 12.6% year over year to $221.17 million, while earnings increased to $0.09 per share from $0.03 a year earlier. However, both figures were below analyst expectations. Alphatec third-quarter earnings report
• Positive Sentiment: Management continues to target a 16% adjusted EBITDA margin for 2026, suggesting an emphasis on profitability and operating efficiency despite slower-than-expected revenue growth. Alphatec lowers fiscal 2026 revenue outlook
• Neutral Sentiment: The company’s quarterly results show continued commercial growth, but Alphatec remains unprofitable, with a negative net margin and analysts expecting a full-year loss. Alphatec third-quarter and nine-month results
• Negative Sentiment: Alphatec lowered its 2026 revenue forecast to $862 million, below the approximately $882 million FactSet estimate. The reduced outlook signals weaker near-term growth than investors had anticipated. Alphatec 2026 revenue outlook
• Negative Sentiment: BMO Capital Markets downgraded ATEC from “outperform” to “market perform” and set an $8.00 price target, implying roughly 29.6% downside from the referenced $11.37 price. BMO Capital Markets Alphatec rating

Analyst Ratings Changes

A number of research firms have weighed in on ATEC. Stifel Nicolaus lowered their target price on Alphatec from $16.00 to $13.00 and set a "buy" rating on the stock in a report on Wednesday, July 8th. Stephens started coverage on Alphatec in a research report on Thursday, July 23rd. They set an "overweight" rating and a $15.00 price objective on the stock. Wall Street Zen lowered Alphatec from a "buy" rating to a "hold" rating in a research note on Sunday, October 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Alphatec in a report on Monday, August 3rd. Finally, TD Cowen reissued a "buy" rating on shares of Alphatec in a research report on Friday. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.00.

Insider Activity

In related news, General Counsel Tyson Marshall sold 8,168 shares of Alphatec stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total transaction of $78,821.20. Following the completion of the transaction, the general counsel directly owned 630,398 shares of the company's stock, valued at approximately $6,083,340.70. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Patrick Miles purchased 115,000 shares of the business's stock in a transaction that occurred on Thursday, September 10th. The shares were purchased at an average price of $8.81 per share, for a total transaction of $1,013,150.00. Following the completion of the acquisition, the chief executive officer directly owned 5,893,551 shares in the company, valued at $51,922,184.31. The trade was a 1.99% increase in their position. The SEC filing for this purchase provides additional information. 13.48% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alphatec

Several hedge funds and other institutional investors have recently modified their holdings of the business. State of Wyoming grew its position in Alphatec by 87.7% in the 3rd quarter. State of Wyoming now owns 30,666 shares of the medical technology company's stock valued at $316,000 after acquiring an additional 14,328 shares during the last quarter. Sterling Capital Management LLC boosted its stake in shares of Alphatec by 841.5% during the third quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company's stock valued at $42,000 after purchasing an additional 3,669 shares during the period. Kopp Family Office LLC boosted its stake in shares of Alphatec by 0.4% during the third quarter. Kopp Family Office LLC now owns 330,266 shares of the medical technology company's stock valued at $3,408,000 after purchasing an additional 1,303 shares during the period. AA Financial Advisors LLC grew its holdings in shares of Alphatec by 140.5% in the third quarter. AA Financial Advisors LLC now owns 48,094 shares of the medical technology company's stock worth $496,000 after purchasing an additional 28,094 shares during the last quarter. Finally, Congress Asset Management Co. grew its holdings in shares of Alphatec by 20.7% in the third quarter. Congress Asset Management Co. now owns 532,069 shares of the medical technology company's stock worth $5,491,000 after purchasing an additional 91,431 shares during the last quarter. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Trading Down 33.3%

The company has a market cap of $1.17 billion, a PE ratio of -10.68 and a beta of 0.78. The company's 50 day moving average is $10.18 and its 200 day moving average is $10.67.

Alphatec Company Profile

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.